Zefiro Boardroom Battle Escalates to Securities Commission Hearing

TORONTO, ON – February 17, 2026 – A bitter corporate governance dispute at Zefiro Methane Corp. (Cboe: ZEFI) is set to come to a head in a regulatory showdown, as the company’s founder and a group of concerned shareholders take their grievances against the current board of directors to the British Columbia Securities Commission (BCSC). The conflict, laden with accusations of board entrenchment and shareholder dilution, places the future leadership and strategic direction of the environmental services firm under intense scrutiny.

Dr. Talal A. Debs, Zefiro’s founder and a significant shareholder, is leading the charge. Along with X Machina Capital Strategies (“XMC”) and X Machina Sustainable Technologies Inc. (“XMST”), the group, which held a 27.5% stake prior to recent share issuances, is asking the BCSC to intervene against what they describe as “oppressive and aggressive defensive tactics.” The hearing, tentatively scheduled for early March, will examine these claims and could result in significant consequences for the company’s board and its upcoming annual general meeting (AGM).

The Heart of the Dispute: A Controversial Share Issuance

The central pillar of the dissidents' complaint is the issuance of 13,214,494 “Debt Settlement Shares” just one day before the record date for the company's AGM. This timing is critical, as it makes the recipients of these new shares eligible to vote in a contentious proxy battle. The shares, representing 14.6% of Zefiro's outstanding stock, were issued to settle debt, but Dr. Debs and his allies argue the move was a calculated entrenchment tactic designed to place votes in “friendly hands.”

The recipients of these shares include Zefiro’s interim CEO and director Catherine Flax, as well as David McGrath and Michael McGavick. The Concerned Shareholders' group highlights that the debt in question was not due for another ten months and that a portion of the shares were issued to cover unaccrued interest, a payment they claim was not obligatory. This has led them to question the business rationale behind the transaction, suggesting its primary purpose was to influence the AGM's outcome.

“The board of directors expects shareholders to believe it was a coincidence that they decided to put 13.2 million newly issued shares into friendly hands one day before the deadline for participating in the proxy contest,” Dr. Debs stated in a press release. “They make accusations of inappropriate behaviour despite consistently showing a willingness to dilute shareholders, failing to adhere to accepted corporate governance standards and spending the Company’s limited cash for the purpose of entrenching and enriching themselves. We look forward to presenting the facts to the BCSC.”

The dissident group is seeking decisive remedies from the BCSC, including the complete rescission of the Debt Settlement Shares or, alternatively, an order preventing them from being voted at the meeting.

Zefiro’s Board Fires Back, Touting a “Proven Recovery”

Zefiro’s current board and management have vigorously defended their actions, dismissing the BCSC application as “inappropriate, unwarranted and without merit.” In public statements, the company has framed the move by Dr. Debs as an attempt to misuse the regulatory process and distract from what it calls his own “poor track record” during his leadership, which ended with his termination for cause in June 2025.

The board provides a starkly different narrative for the share issuance. They contend that the debt settlement was a prudent financial decision designed to eliminate approximately USD$1.79 million in debt and strengthen the company's balance sheet. Furthermore, Zefiro claims that the vast majority of the shares—over 10.7 million—were issued pursuant to the exercise of warrants that Dr. Debs himself had approved in May 2025. The company also noted that the dissident shareholders were offered the chance to subscribe for their portion of the newly issued shares but declined to do so.

Management is positioning the conflict as a choice between a troubled past and a promising future. They point to a “proven recovery” since the leadership change, citing stabilized operations, restored financial discipline, and a material recovery in shareholder value. The company recently reported strong fiscal Q2 2026 results, with over USD$22 million in revenue for the first six months of the fiscal year and a return to profitability, which they argue is evidence of the current strategy's success. The board also highlights that Dr. Debs is facing a company investigation for potential misconduct and is named in lawsuits alleging serious financial misconduct in other entities he controls, suggesting his return would introduce unnecessary risk.

A Pattern of Alleged Entrenchment Tactics

Beyond the pivotal debt-for-equity swap, Dr. Debs’s group has outlined a series of other actions by the board that they believe demonstrate a pattern of entrenchment. These allegations include:

• Amending employment agreements to include generous and allegedly off-market change-of-control bonuses for interim CEO Catherine Flax and other executives.
• Altering the company’s Advance Notice Policy in a manner the dissidents call unprecedented, granting the board discretionary power to disqualify director nominees.
• Breaching and ultimately invalidating an Investor Rights Agreement held by one of Dr. Debs’s affiliated entities.
• Failing to call the annual general meeting on a timely basis, a move the dissidents see as a delay tactic.

These actions, taken together, paint a picture of a board actively working to consolidate its power and insulate itself from shareholder challenges, according to the Concerned Shareholders. The company, in turn, views these moves as necessary steps taken by an independent board to protect the company from a disruptive former executive.

Regulatory Scrutiny and Market Uncertainty

The upcoming BCSC hearing places the regulator in the difficult position of arbitrating a high-stakes corporate power struggle. The commission’s decision could have far-reaching implications, not only for Zefiro Methane Corp. but also for corporate governance standards in Canada. A ruling in favor of Dr. Debs could set a precedent regarding the use of debt settlements and other defensive measures during proxy contests.

Meanwhile, the market has reacted with predictable volatility. Zefiro’s stock (ZEFI) has underperformed its industry peers over the past year, reflecting the uncertainty surrounding the internal conflict. Investor sentiment appears sharply divided, with active discussions in online forums showing support for both management's recovery narrative and the founder's fight for shareholder rights. The AGM, originally scheduled for March 4, is now expected to be postponed to allow shareholders to consider the outcome of the BCSC hearing before casting their votes.

As both sides prepare to present their cases, shareholders are left to weigh the dueling narratives. One side promises a continued recovery under proven leadership, while the other calls for a return to founder-led principles and an end to alleged self-serving governance. The BCSC’s ruling will be a critical inflection point, likely determining which vision will guide Zefiro Methane's path forward.